NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $9.74 +0.34 (+3.62%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$9.64 -0.10 (-0.99%) As of 08/8/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PHAT alerts:Sign Up Key Stats Today's Range$9.34▼$9.9850-Day Range$4.64▼$10.9052-Week Range$2.21▼$19.71Volume1.37 million shsAverage Volume1.05 million shsMarket Capitalization$690.96 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingBuy Company Overview Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Read More Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScorePHAT MarketRank™: Phathom Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 367th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.78) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.66% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 13.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.66% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 13.73%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.05 News SentimentPhathom Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Phathom Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest11 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have bought 3.15% more of their company's stock than they have sold. Specifically, they have bought $14,591.00 in company stock and sold $14,145.00 in company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Stock News HeadlinesRobert Charles Breedlove Sells 1,692 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 19, 2025 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $17.50 Consensus Target Price from AnalystsAugust 10 at 2:49 AM | americanbankingnews.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineAugust 9 at 8:01 PM | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call TranscriptAugust 9 at 9:33 AM | insidermonkey.comPhathom (PHAT) Q2 Revenue Jumps 441%August 8 at 8:18 AM | theglobeandmail.comPhathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growthAugust 8 at 8:18 AM | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $8.12 at the beginning of the year. Since then, PHAT stock has increased by 20.0% and is now trading at $9.74. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings data on Thursday, November, 7th. The company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.57) by $0.25. The firm had revenue of $16.35 million for the quarter, compared to analysts' expectations of $12.54 million. Read the conference call transcript. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' top institutional investors include Geode Capital Management LLC (1.53%), Simplify Asset Management Inc. (0.75%), Creative Planning (0.08%) and AlphaQuest LLC (0.05%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh, Molly Henderson, James N Topper, Frank Karbe and Robert Charles Breedlove. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings11/07/2024Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAT CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Phathom Pharmaceuticals$17.50 High Price Target$28.00 Low Price Target$5.00 Potential Upside/Downside+79.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$334.33 million Net Margins-289.51% Pretax Margin-422.42% Return on EquityN/A Return on Assets-83.82% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio3.54 Sales & Book Value Annual Sales$114.04 million Price / Sales5.96 Cash FlowN/A Price / Cash FlowN/A Book Value($3.71) per share Price / Book-2.63Miscellaneous Outstanding Shares69,814,000Free Float53,757,000Market Cap$679.99 million OptionableOptionable Beta0.45 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PHAT) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.